| Document |
Document Title |
|
WO/2021/110968A9 |
The present disclosure provides macrocyclic compounds comprising a 4-amido- 2,4-pentadienoate (APD) moiety. The compounds exhibit toxicity that is selective to the hypoxic micro-environments often found in cancerous tissues. The disclose...
|
|
WO/2022/127704A1 |
Disclosed are a method for preparing a carboxyl cyclic acid anhydride and a prepared product thereof. A method for preparing a compound of formula (II), comprising the steps of reacting a compound of formula (I) with a cyclization reagen...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
|
WO/2022/125800A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/123541A1 |
The present disclosure relates to a process for the preparation of pyrazole-oxadiazepine. The process of the present disclosure reduces solvent use, uses inexpensive and easily available reagents. The process is simple, efficient, enviro...
|
|
WO/2022/109117A1 |
The present invention is directed to 3-amino pyrrolidine and piperidine macrocyclic compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treat...
|
|
WO/2022/103899A1 |
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
|
|
WO/2022/076563A1 |
The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.
|
|
WO/2022/069563A1 |
The invention relates to a water-dispersible modified polyisocyanate and use thereof, especially as a crosslinking component in water-soluble or water-dispersible coating compositions. The water-dispersible modified polyisocyanate can be...
|
|
WO/2022/071970A1 |
Compositions with supramolecular structures for use in agricultural methods include a source of micronutrients such as a fertilizer, a supramolecular host chemical or a supramolecular guest chemical configured to engage in host-guest che...
|
|
WO/2022/048025A1 |
The present invention provides a method for synthesizing an atorvastatin calcium intermediate by using a multi-component one-pot method. Specifically, the present invention provides a one-pot synthesis method for 4-(4-fluorophenyl)-2-(2-...
|
|
WO/2021/250240A1 |
The invention relates to a diaza-18-crown-6 derivative having formula (I): wherein: B is a moiety for a covalent bonding reaction; the two A are identical to each other and are a group of formula (II): where: n = 0 to 4; X1, X2, X3, X4 a...
|
|
WO/2021/191035A1 |
The invention relates to compounds of formula (I), (I) and their use as herbicides. In said formula, R1 to R7 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a diva...
|
|
WO/2021/188620A1 |
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sa...
|
|
WO/2021/175225A1 |
Disclosed in the present invention are a series of tricyclic compounds, and particularly disclosed are a compound shown in formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/175223A1 |
Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/168567A1 |
A chelator having the general structure (I) for chelating radiometals such as 225Ac under mild conditions is provided. (I) The chelator can be coupled to a biological targeting moiety to facilitate targeted delivery of the chelated radio...
|
|
WO/2021/149767A1 |
Provided are: a heterocyclic derivative and/or a pharmaceutically acceptable salt thereof that can serve as a therapeutic agent and/or a prophylactic agent for a disease in which the sodium channel (Nav) is involved and for various centr...
|
|
WO/2021/123036A1 |
The present invention relates to use of a chelating compound (I) for chromatographic separation of rare earth elements, actinides, and/ or s-, p- and d-block metals, and to a method of chromatographic separation of chelates of rare earth...
|
|
WO/2021/047308A1 |
Disclosed are a polyisocyanate composition and a method for preparing the composition. The composition is formed by polymerizing an aliphatic diisocyanate monomer at least including hexamethylene diisocyanate, and contains an isocyanurat...
|
|
WO/2021/008908A1 |
The invention relates to a method for producing polyisocyanates having a low monomer content, said method comprising the following steps: (i) modifying at least one monomeric diisocyanate to obtain a mixture containing at least one polyi...
|
|
WO/2021/005545A1 |
The present disclosure relates to a process for obtaining an enantiomeric mixture of Indoxacarb crystals having purity in the range of 95% to 99.5%, wherein the enantiomeric mixture comprises crystals of R-isomer and S-isomer. The S-isom...
|
|
WO/2020/157188A1 |
The present invention provides dihydrooxydiazinone compounds of general formula (I) : (I), in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compound...
|
|
WO/2020/160100A1 |
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
|
|
WO/2020/157201A1 |
The present invention includes name compounds of general formula (I) in which R1, Y, and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositio...
|
|
WO/2020/109189A1 |
The present invention relates to a modified polyisocyanate and use thereof, in particular as a crosslinking component of water-soluble or water-dispersible coatings. The modified polyisocyanate is obtained by a reaction of a system compr...
|
|
WO/2020/097950A1 |
Disclosed is a method for preparing polyisocyanate. A self-polymerization reaction of isocyanate is carried out using a fluorine-containing catalyst as a catalyst. After the reaction is completed, a fluorine-containing terminator is adde...
|
|
WO/2020/014524A1 |
This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-...
|
|
WO/2019/217449A1 |
The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R1, R2, R3, R4, L1, and L2 are as defined herein. The present invention also contemplates ...
|
|
WO/2019/154288A1 |
Disclosed in the present invention are a cationic compound, a preparation method therefor and a use thereof. Provided by the present invention is a compound represented by formula I having a novel structure, or a pharmaceutically accepta...
|
|
WO/2019/135604A1 |
The present invention relates to a method for producing a lactam compound from dioxazolone in the presence of a catalyst having a particular ligand, and to a lactam compound produced thereby, and can produce a lactam compound with excell...
|
|
WO/2019/109402A1 |
The present invention pertains to the technical field of pesticides, and particularly relates to a dioxazine derivative, a preparation method therefor, an herbicidal composition containing the same, and an application thereof. The chemic...
|
|
WO/2019/091975A1 |
The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.
|
|
WO/2019/087087A1 |
The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programme...
|
|
WO/2019/055657A1 |
The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and pro...
|
|
WO/2019/052545A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in b...
|
|
WO/2019/034660A1 |
The invention relates to a method for producing polyisocyanates which comprise at least 10 mol% of iminooxadiazinedione groups based on the sum total of the iminooxadiazinedione and isocyanurate groups present in the polyisocyanate, by r...
|
|
WO/2019/025562A1 |
The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ph...
|
|
WO/2018/206635A1 |
The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an act...
|
|
WO/2018/197523A1 |
The invention relates to novel compounds of formula (I) and their use in medicine, particularly in treating and /or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Additionally, the i...
|
|
WO/2018/178982A1 |
It is an object of the present invention to provide a novel and advantageous process for commercially preparing of indoxacarb which is racemic or enantiomerically enriched at chiral center from its amide precursor using a new catalytic s...
|
|
WO/2018/157813A1 |
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...
|
|
WO/2018/137387A1 |
Provides a crystalline form of indoxacarb, the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. Also provides the use of various...
|
|
WO/2018/120093A1 |
Provided are a process for preparing an oxadiazacyclo compound and the use thereof. An N-alkoxycarbonyl hydrazine is cyclized with a disubstituted ether under the action of an alkali to give an N-alkoxycarbonyl oxadiazacyclo compound, an...
|
|
WO/2018/093920A1 |
The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the natural...
|
|
WO/2018/089951A1 |
Chemoselective conjugation is achieved through redox reactivity by reacting an N- transfer oxidant with a thioether substrate in a redox reaction in an aqueous environment to form a conjugation product. In embodiments, Redox-Activated Ch...
|
|
WO/2018/039430A1 |
Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [18F]IDO49 specifically accumulate in IDO-expres...
|
|
WO/2018/009417A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.
|
|
WO/2017/202481A1 |
The invention relates to the use of l-(4,6-dipentyl-5,6- dihydro-2H-l,2,3-oxadiazin-2-yl)-3-hydroxypropan-l-one in treating and /or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Add...
|
|
WO/2017/194452A1 |
The present invention relates to seco (opened ring) macrolide compounds of formula (I), to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, ...
|
